CDN1163

CDN1163 is an allosteric sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA) activator that improves Ca²⁺ homeostasis. CDN1163 attenuates diabetes and metabolic disorders^[1]. IC50 & Target: SERCA^[1] In Vitro: CDN1163 (10 μM; 24 hours; rat cardiac myocyte cells) treatment reduces high glucose-induced resistin and nuclear NFATc expression and increases the phosphorylation of AMPKα in a time-dependent manner^[2]. In Vivo: CDN1163 (50 mg/kg; intraperitoneal injection; for 5 days; male ob/ob mice and lean ob/+ mice) increases SERCA2 Ca²⁺-ATPase activity, decreases endoplasmic reticulum (ER) stress-induced cell death in vitro and improves liver Ca²⁺ transport activity. CDN1163 reduces blood glucose levels and improves metabolic parameters and gluconeogenic gene expression, reverses hepatic steatosis, inhibits ER stress and ER stress-induced apoptosis, and improves mitochondrial efficiency in ob/ob mice in vivo^[1].